Activation of Immune Responses Through the RIG-I Pathway Using TRITC-Dextran Encapsulated Nanoparticles

키워드

참고문헌 (95)

1. Khan I, "Nanoparticles : properties, applications and toxicities", Arab J Chem, 12, pp.908~931 (2019)
2. Khan S, "A review on nanotechnology : properties, applications, and mechanistic insights of cellular uptake mechanisms", J Mol Liq, 348, pp.118008~ (2022)
3. Yao Y, "Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance", Front Mol Biosci, 7, pp.193~ (2020)
4. Liu Y, "Effects of engineered nanoparticles on the innate immune system", Semin Immunol, 34, pp.25~32 (2017)
5. Aljabali AA, "Nanomaterials and their impact on the immune system", Int J Mol Sci, 24, pp.2008~ (2023)
6. Zhao T, "Vaccine adjuvants : mechanisms and platforms", Signal Transduct Target Ther, 8, pp.283~ (2023)
7. Zhou J, "Biomimetic nanotechnology toward personalized vaccines", Adv Mater, 32, pp.e1901255~ (2020)
8. Peek LJ, "Nanotechnology in vaccine delivery", Adv Drug Deliv Rev, 60, pp.915~928 (2008)
9. Kobayashi K, "Surface engineering of nanoparticles for therapeutic applications", Polym J, 46, pp.460~468 (2014)
10. El-Sherbiny IM, "Janus nano-and microparticles as smart drug delivery systems", Curr Pharm Biotechnol, 17, pp.673~682 (2016)
11. Li H, "Functionalized silica nanoparticles : classification, synthetic approaches and recent advances in adsorption applications", Nanoscale, 13, pp.15998~16016 (2021)
12. Boraschi D, "Nanoparticles and innate immunity : new perspectives on host defence", Semin Immunol, 34, pp.33~51 (2017)
13. Dobrovolskaia MA, "Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution", Mol Pharm, 5, pp.487~495 (2008)
14. Liu J, "The interaction between nanoparticles and immune system : application in the treatment of inflammatory diseases", J Nanobiotechnology, 20, pp.127~ (2022)
15. Bamberger D, "Surface modification of polysaccharide-based nanoparticles with PEG and dextran and the effects on immune cell binding and stimulatory characteristics", Mol Pharm, 14, pp.4403~4416 (2017)
16. Saito T, "Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity", J Exp Med, 205, pp.1523~1527 (2008)
17. Rehwinkel J, "RIG-I-like receptors : their regulation and roles in RNA sensing", Nat Rev Immunol, 20, pp.537~551 (2020)
18. Thoresen D, "The molecular mechanism of RIG-I activation and signaling", Immunol Rev, 304, pp.154~168 (2021)
19. Kell AM, "RIG-I in RNA virus recognition", Virology, 479-480, pp.110~121 (2015)
20. Iurescia S, "The innate immune signalling pathways : turning RIG-I sensor activation against cancer", Cancers(Basel), 12, pp.3158~ (2020)
21. Yong HY, "RIG-I-like receptors as novel targets for pan-antivirals and vaccine adjuvants against emerging and re-emerging viral infections", Front Immunol, 9, pp.1379~ (2018)
22. Hemann EA, "A small molecule RIG-I agonist serves as an adjuvant to induce broad multifaceted influenza virus vaccine immunity", J Immunol, 210, pp.1247~1256 (2023)
23. Jiang Y, "Exploiting RIG-I-like receptor pathway for cancer immunotherapy", J Hematol Oncol, 16, pp.8~ (2023)
24. Jacobson ME, "Structural optimization of polymeric carriers to enhance the immunostimulatory activity of molecularly defined RIG-I agonists", ACS Cent Sci, 6, pp.2008~2022 (2020)
25. Vanpouille-Box C, "Pharmacological modulation of nucleic acid sensors-therapeutic potential and persisting obstacles", Nat Rev Drug Discov, 18, pp.845~867 (2019)
26. Zillinger T, "Targeted nanoparticle delivery of bifunctional RIG-I agonists to pancreatic cancer", Mol Ther, 27, pp.491~492 (2019)
27. Wright JF, "AAV vector manufacturing process design and scalability-Bending the trajectory to address vector-associated immunotoxicities", Mol Ther, 30, pp.2119~2121 (2022)
28. Yoo YJ, "Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy", J Control Release, 343, pp.564~583 (2022)
29. Angehrn Z, "Artificial intelligence and machine learning applied at the point of care", Front Pharmacol, 11, pp.759~ (2020)
30. Carmona-Ribeiro AM, "Supramolecular nanostructures for vaccines", Biomimetics(Basel), 7, pp.6~ (2021)
31. Kamaly N, "Degradable controlled-release polymers and polymeric nanoparticles : mechanisms of controlling drug release", Chem Rev, 116, pp.2602~2663 (2016)
32. Hou X, "Lipid nanoparticles for mRNA delivery", Nat Rev Mater, 6, pp.1078~1094 (2021)
33. Mehta M, "Lipid-based nanoparticles for drug", gene delivery : an overview of the production techniques and difficulties encountered in their industrial development, 2023, pp.3, 600~619
34. Dilliard SA, "Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs", Nat Rev Mater, 8, pp.282~300 (2023)
35. Lokugamage MP, "Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs", Nat Biomed Eng, 5, pp.1059~1068 (2021)
36. Marx S, "RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection", Mol Ther Nucleic Acids, 27, pp.1225~1234 (2022)
37. Wang-Bishop L, "Nanoparticle retinoic acid-inducible gene I agonist for cancer immunotherapy", ACS Nano, 18, pp.11631~11643 (2024)
38. Cristóbal I, "A complex microRNA regulatory network may control the HCP5", UTP3, VAMP3 signaling axis, pp.Mol Ther, 2023[DOI]
39. Carneiro BA, "Targeting apoptosis in cancer therapy", Nat Rev Clin Oncol, 17, pp.395~417 (2020)
40. Lucy TT, "Serial passaging of RAW 264. 7 cells modulates intracellular AGE formation and downregulates RANKL-induced in vitro osteoclastogenesis", Int J Mol Sci, 23, pp.2371~ (2022)
41. Kim KM, "Intestinal anti-inflammatory activity of Sasa quelpaertensis leaf extract by suppressing lipopolysaccharide-stimulated inflammatory mediators in intestinal epithelial Caco-2 cells co-cultured with RAW 264. 7 macrophage cells", Nutr Res Pract, 9, pp.3~10 (2015)
42. Xian H, "Stratified ubiquitination of RIG-I creates robust immune response and induces selective gene expression", Sci Adv, 3, pp.e1701764~ (2017)
43. Huang Z, "RIG-I contributes to dsDNA-induced innate immune activation in human brain microvascular endothelial cells", Mol Immunol, 152, pp.78~85 (2022)
44. Plociennikowska A, "TLR3 activation by Zika virus stimulates inflammatory cytokine production which dampens the antiviral response induced by RIG-I-like receptors", J Virol, 95, pp.e01050-20~ (2021)
45. Mohamed A, "Closely related reovirus lab strains induce opposite expression of RIG-I", IFN-dependent versus-independent host genes, via mechanisms of slow replication versus polymorphisms in dsRNA binding σ3 respectively, 2020, pp.16, e1008803~
46. Minchin S, "Understanding biochemistry : structure and function of nucleic acids", Essays Biochem, 63, pp.433~456 (2019)
47. van den Berg AIS, "Polymeric delivery systems for nucleic acid therapeutics : approaching the clinic", J Control Release, 331, pp.121~141 (2021)
48. Palmer CR, "Environmentally triggerable retinoic acid-inducible gene I agonists using synthetic polymer overhangs", Bioconjug Chem, 29, pp.742~747 (2018)
49. Sardone V, "Antisense oligonucleotide-based therapy for neuromuscular disease", Molecules, 22, pp.563~ (2017)
50. Paunovska K, "Drug delivery systems for RNA therapeutics", Nat Rev Genet, 23, pp.265~280 (2022)
51. Das M, "Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer", Mol Ther, 27, pp.507~517 (2019)
52. Peng B, "Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy", J Extracell Vesicles, 11, pp.e12187~ (2022)
53. Brisse M, "Comparative structure and function analysis of the RIG-I-like receptors : RIG-I and MDA5", Front Immunol, 10, pp.1586~ (2019)
54. Onomoto K, "Regulation of RIG-I-like receptor-mediated signaling : interaction between host and viral factors", Cell Mol Immunol, 18, pp.539~555 (2021)
55. Wu Q, "Dextran-coated superparamagnetic iron oxide nanoparticles activate the MAPK pathway in human primary monocyte cells", Mol Med Rep, 18, pp.564~570 (2018)
56. Bharde AA, "Magnetic nanoparticles as mediators of ligand-free activation of EGFR signaling", PLoS One, 8, pp.e68879~ (2013)
57. Maggi LB Jr, "ERK activation is required for double-stranded RNA-and virus-induced interleukin-1 expression by macrophages", J Biol Chem, 278, pp.16683~16689 (2003)
58. Dou H, "The one-pot synthesis of dextran-based nanoparticles and their application in in-situ fabrication of dextran-magnetite nanocomposites", J Mater Sci Mater Med, 19, pp.2575~2580 (2008)
59. Kawaguchi T, "Dextran-magnetite complex : conformation of dextran chains and stability of solution", J Mater Sci Mater Med, 12, pp.121~127 (2001)
60. Priya S, "Polysaccharide-based nanofibers for pharmaceutical and biomedical applications : a review", Int J Biol Macromol, 218, pp.209~224 (2022)
61. Luanda A, "Past, present and future of biomedical applications of dextran-based hydrogels : a review", Int J Biol Macromol, 228, pp.794~807 (2023)
62. Hu Q, "Recent advances in dextran-based drug delivery systems : From fabrication strategies to applications", Carbohydr Polym, 264, pp.117999~ (2021)
63. Wang S, "Acetalated dextran based nano-and microparticles : synthesis, fabrication, and therapeutic applications", Chem Commun(Camb), 57, pp.4212~4229 (2021)
64. Tassa C, "Dextran-coated iron oxide nanoparticles : a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy", Acc Chem Res, 44, pp.842~852 (2011)
65. Kunc F, "Polycarboxylated dextran as a multivalent linker : synthesis and target recognition of the antibody-nanoparticle bioconjugates in PBS and serum", Langmuir, 35, pp.4909~4917 (2019)
66. Ahmad T, "Ni-Fe2O4 nanoparticles as contrast agents for magnetic resonance imaging", J Nanosci Nanotechnol, 11, pp.5645~5650 (2011)
67. Lee H, "Thermally cross-linked superparamagnetic iron oxide nanoparticles : synthesis and application as a dual imaging probe for cancer in vivo", J Am Chem Soc, 129, pp.12739~12745 (2007)
68. Moore CJ, "Controlling colloidal stability of silica nanoparticles during bioconjugation reactions with proteins and improving their longer-term stability, handling and storage", J Mater Chem B Mater Biol Med, 3, pp.2043~2055 (2015)
69. Khan MS, "Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer", Int J Pharm, 643, pp.123276~ (2023)
70. Vocelle D, "Dextran functionalization enhances nanoparticle-mediated siRNA delivery and silencing", Technology(Singap), 4, pp.42~54 (2016)
71. Dubois A, "Enhanced anti-HCV activity of interferon alpha 17 subtype", Virol J, 6, pp.70~ (2009)
72. West AP, "TLR signalling augments macrophage bactericidal activity through mitochondrial ROS", Nature, 472, pp.476~480 (2011)
73. Kawauchi Y, "Comparison of the carbohydrate preference of SIGNR1 as a phagocytic receptor with the preference as an adhesion molecule", Int Immunopharmacol, 19, pp.27~36 (2014)
74. Rennick JJ, "Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics", Nat Nanotechnol, 16, pp.266~276 (2021)
75. Antonio LC, "The amount of dextran in PLGA nanocarriers modulates protein corona and promotes cell membrane damage", J Mater Chem B Mater Biol Med, 10, pp.8282~8294 (2022)
76. Berry CC, "Cell response to dextran-derivatised iron oxide nanoparticles post internalisation", Biomaterials, 25, pp.5405~5413 (2004)
77. Wilhelm C, "Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating", Biomaterials, 24, pp.1001~1011 (2003)
78. Motta V, "NOD-like receptors : versatile cytosolic sentinels", Physiol Rev, 95, pp.149~178 (2015)
79. Man SM, "Regulation of inflammasome activation", Immunol Rev, 265, pp.6~21 (2015)
80. Sun L, "Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway", Science, 339, pp.786~791 (2013)
81. Li S, "Cytosolic and nuclear recognition of virus and viral evasion", Mol Biomed, 2, pp.30~ (2021)
82. Ramasundaram S, "Dextran sulfate nanocarriers : design, strategies and biomedical applications", Int J Mol Sci, 24, pp.355~ (2022)
83. Pansailom N, "Surface modification : PEG", dextran encapsulation of SPIONs, 2017, pp.4, 6306~6310
84. Zeini D, "Influence of lysine and TRITC conjugation on the size and structure of dextran nanoconjugates with potential for biomolecule delivery to neurons", ACS Appl Bio Mater, 4, pp.6832~6842 (2021)
85. Thoresen DT, "A rapid RIG-I signaling relay mediates efficient antiviral response", Mol Cell, 83, pp.90~104 (2023)
86. Burkart SS, "High-resolution kinetic characterization of the RIG-I-signaling pathway and the antiviral response", Life Sci Alliance, 6, pp.e202302059~ (2023)
87. Jiang M, "Self-recognition of an inducible host lncRNA by RIG-I feedback restricts innate immune response", Cell, 173, pp.906~919 (2018)
88. Murakami T, "Structural and functional changes in high-density lipoprotein induced by chemical modification", Biomater Sci, 3, pp.712~715 (2015)
89. Gao S, "Dextran-coated nanoparticles as immunosensing platforms : Consideration of polyaldehyde density, nanoparticle size and functionality", Talanta, 247, pp.123549~ (2022)
90. Mitchell MJ, "Engineering precision nanoparticles for drug delivery", Nat Rev Drug Discov, 20, pp.101~124 (2021)
91. Chenthamara D, "Therapeutic efficacy of nanoparticles and routes of administration", Biomater Res, 23, pp.20~ (2019)
92. Manolova V, "Nanoparticles target distinct dendritic cell populations according to their size", Eur J Immunol, 38, pp.1404~1413 (2008)
93. Taback B, "Molecular lymphatic mapping of the sentinel lymph node", Am J Pathol, 161, pp.1153~1161 (2002)
94. Chaney EJ, "Lymphatic biodistribution of polylactide nanoparticles", Mol Imaging, 9, pp.153~162 (2010)
95. McLennan DN, "Subcutaneous drug delivery and the role of the lymphatics", Drug Discov Today Technol, 2, pp.89~96 (2005)

관련 논문AI추천